- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06319274
Infusion of Prostacyclin vs Placebo for 72-hours in Mechanically Ventilated Patients With Acute Respiratory Failure (COMBAT-ARF)
Efficacy and Safety of 72-hour Infusion of Prostacyclin (1 ng/kg/Min) in Mechanically Ventilated Patients With Infectious Pulmonary Endotheliopathy - a Multicenter Randomized, Placebo-controlled, Blinded, Investigator-initiated Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Acute respiratory failure (ARF) is common in critically ill patients and 50% of all intensive care unit patients require mechanical ventilation. ARF occurs in a heterogenous patient group, most often in the setting of pneumonia, sepsis, aspiration of gastric contents or severe trauma and major surgery. Despite improvements in intensive care capabilities, ARF mortality remains high and the only treatment option, to date, is supportive care. A recent Cochrane analysis (2018) found no evidence for that any drug was effective in reducing deaths in mechanically ventilated patients with ARF, highlighting the high unmet medical need.
Given that the pulmonary system, apart from the brain, is the most highly vascularized vital organ in the body, extensive endothelial damage is a central feature of acute respiratory distress syndrome (ARDS) with respiratory failure being the rationale for the current study. Evidence support that iloprost infusion significantly improved endothelial function and integrity in mechanically ventilated patients with COVID-19 infection with reducing 28-day mortality by 50%.
The main objective in this clinical trial is to investigate whether continuous infusion of low dose iloprost at a dose of 1 ng/kg/min for 72-hours is safe and significantly reduce all-cause mortality at day 28.
Patients that are eligible for this trial will be temporarily incompetent due to acute severe illness relating to respiratory failure.
During the trial, patient will be given continuous infusion of low dose iloprost or placebo for 72 hours during their stay at the intensive care unit (ICU) and additional blood samples will be obtained at baseline, 24-, 48 and 72-hours.
This trial is conducted in accordance with the Helsinki 2 Declaration and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Guideline for Good Clinical Practice (ICH-GCP) and in compliance with the protocol. As part of the quality assurance on-site monitoring visit will be performed by the an independent GCP-unit including source data verification. Standard Operation Procedure (SOP) will address protocol specific procedures.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Pär I Johansson, MD, DMSc
- Phone Number: +4535452030
- Email: per.johansson@regionh.dk
Study Contact Backup
- Name: Kristine H Pedersen, MSc. Pharm.
- Phone Number: +4535453489
- Email: kristine.holst.pedersen.01@regionh.dk
Study Locations
-
-
-
Copenhagen, Denmark, 2400
- Dept. of Anaesthesia and Intensive Care, Bispebjerg Hospital
-
Contact:
- Niels E Clausen, MD
-
Principal Investigator:
- Niels E Clausen, MD
-
Herlev, Denmark, 2730
- Dept. of Intensive Care, Copenhagen University Hospital Herlev
-
Contact:
- Peter Soee-Jensen, MD
-
Principal Investigator:
- Peter Soee-Jensen, MD
-
Hillerød, Denmark, 3400
- Dept. of Anaesthesia and Intensive Care, Nordsjaelands Hospital
-
Principal Investigator:
- Morten Bestle, MD
-
Contact:
- Morten Bestle, MD
-
Køge, Denmark, 4600
- Department of Anesthesia and Intensive Care Medicine, Zealand University Hospital
-
Contact:
- Lars Peter K Andersen, MD, PhD
-
Principal Investigator:
- Lars Peter K Andersen, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult intensive care patients (age ≥ 18 years)
- Suspected pulmonary infection
- Need for mechanical ventilation (< 24 hours from time of screening)
- soluble thrombomodulin (sTM) ≥ 4 ng/mL in blood plasma
Exclusion Criteria:
- Withdrawal from active therapy
- Pregnancy (non-pregnancy confirmed by patient having a negative urine- or plasma Choriogonadotropin (hCG) or being postmenopausal defined as females at 60 years old or beyond or at the investigators discretion)
- Septic shock according to the Sepsis 3 criteria AND a sTM> 10 ng/ml
- Known hypersensitivity to iloprost or to any of the other ingredients.
- Previously included in this trial or a prostacyclin trial within 30 days
- Life-threatening bleeding defined by the treating physician
- Known severe heart failure (NYHA class IV)
- Suspected acute coronary syndrome
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Iloprost
Patients randomized to active treatment (n=225 patients) will receive continuous infusion of iloprost for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
|
Continuously infusion for 72 hours at 3 ml/hours.
Treatment dose 1 ng/kg/min
Other Names:
|
Placebo Comparator: Isotonic saline
Patients randomized to placebo treatment (n=225 patients) will receive continuous infusion of placebo for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
|
Continuously infusion for 72 hours at 3 ml/hours
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
28-day mortality
Time Frame: Day 28
|
All-cause mortality at day 28
|
Day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
90-day mortality
Time Frame: Day 90
|
All-cause mortality at day 90
|
Day 90
|
Vasopressor-free days
Time Frame: Until ICU discharge, maximun 90 days after randomization]
|
Days alive without vasopressor in the ICU within 28- and 90 days
|
Until ICU discharge, maximun 90 days after randomization]
|
Renal replacement-free days
Time Frame: Until ICU discharge, maximun 90 days after randomization]
|
Days alive without renal replacement in the ICU within 28- and 90 days
|
Until ICU discharge, maximun 90 days after randomization]
|
Mechanical ventilation free days
Time Frame: Until ICU discharge, maximun 90 days after randomization]
|
Days alive without mechanical ventilation in the ICU within 28- and 90 days
|
Until ICU discharge, maximun 90 days after randomization]
|
Serious adverse reactions (SARs)
Time Frame: Until day 7 after randomization
|
Total number and numbers of patient with one or more serious adverse reactions within the first 7 days
|
Until day 7 after randomization
|
Serious adverse events (SAEs)
Time Frame: Until day 7 after randomization
|
Total numbers and numbers of patients with one or more serious adverse events within the first 7 days
|
Until day 7 after randomization
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Pär I Johansson, MD, DMSc, Rigshospitalet, Denmark
- Principal Investigator: Peter Soee-Jensen, MD, +4538682458
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- COMBAT-ARF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endothelial Dysfunction
-
M.D. Anderson Cancer CenterRecruitingEndothelial Dysfunction | Vascular | Endothelial | EndothelixUnited States
-
Clinica ARS MedicaUnknown
-
University of California, San DiegoCompletedEndothelial Dysfunction
-
M.D. Anderson Cancer CenterCompletedEndothelial DysfunctionUnited States
-
NestléCompleted
-
Société des Produits Nestlé (SPN)Completed
-
General Hospital of Chinese Armed Police ForcesChinese PLA General HospitalUnknown
-
University of ConnecticutCompletedEndothelial DysfunctionUnited States
-
Florida State UniversityRecruitingEndothelial DysfunctionUnited States
-
Poznan University of Physical EducationCompletedEndothelial DysfunctionPoland
Clinical Trials on Iloprost
-
University of OklahomaCompletedChronic Obstructive Pulmonary Disease | Pulmonary HypertensionUnited States
-
Charite University, Berlin, GermanySchering-PloughTerminatedSystemic SclerosisGermany
-
ActelionTerminatedPulmonary Arterial HypertensionUnited States
-
ActelionTerminatedPulmonary HypertensionUnited States
-
Loma Linda UniversityWithdrawnHypoxic Pulmonary VasoconstrictionUnited States
-
National Center for Research Resources (NCRR)University of PittsburghCompletedSystemic Sclerosis | Raynaud Disease
-
Lund University HospitalBayerWithdrawnRespiratory Distress Syndrome | Persistent Pulmonary HypertensionSweden
-
University of Colorado, DenverNational Cancer Institute (NCI)CompletedLung Cancer | Precancerous ConditionUnited States
-
BayerCompletedHypertension, PulmonaryItaly, Spain, France, Germany, Portugal, United Kingdom
-
University of ChicagoTerminatedPulmonary HypertensionIsrael, United States